¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"proximal clot"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • proximal interphalangeal joint
    ±ÙÀ§Áö°£ °üÀý(ÐÎêÈò¦Êàμï½).
  • proximal lingual tubercle
    ¸öÂÊÇô°áÀý
  • proximal muscle
    ±ÙÀ§±Ù(ÐÎêÈÐÉ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma clot
    Ç÷À屫(úìíìÎÔ)
  • red cruor clot
    Àû»öÀÀÇ÷±«(îåßäëêúìÎÔ)
  • whole blood clot lysis time
    ÀüÇ÷Ç÷º´À¶ÇØ<--¿ëÇØ>½Ã°£
  • approximate caries =proximal c.
    ÀÎÁ¢¸é ¿ì½Ä(ìäïÈØüó»ãÚ).
  • distal proximal cavity
    ¿ø½É¸é¿Íµ¿ (¡­ØüèÀ÷Ó).
  • distal proximal surface
    ¿ø½ÉÀÎÁ¢¸é (¡­ìäïÈØü).
  • nerve, proximal facial
    ±ÙÀ§¾È¸é½Å°æ
  • proximal
    ¸öÂÊ
  • proximal caries
    ÀÎÁ¢¸é¿ì½Ä(ìäïÈØüó»ãÝ).
  • proximal centriole
    ¸Ó¸®ÂÊÁ߽ɼÒü
  • proximal cephalic vein
    ±ÙÀ§ µÎ(ºÎ)Á¤¸Æ
  • proximal common pathway
    ±ÙÀ§°øÅë°æ·Î.
  • proximal contact
    ÀÎÁ¢(ìäïÈ).
  • proximal convergence
    ±ÙÁ¢(½Ã)´«¸ðÀ½, ±ÙÁ¢(½Ã)ÆøÁÖ
  • proximal convoluted tubule
    Å丮Âʰö½½¼¼°ü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DBCL dilute blood clot lysis [method]
ECL emitter-coupled logic; enterochromaffin-like [type]; euglobin clot lysis
ECLT euglobulin clot lysis time
ECT electroconvulsive therapy; emission computed tomography; enteric coated tablet; euglobulin clot test...
MCP maximum closure pressure; maximum contraction pattern; malanocortin receptor; melphalan, cyclophosph...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PCT Proximal convoluted tubule
PFFD Proximal femoral focal deficiency
PGV Proximal gastric vagotomy
PIP Proximal interphalangeal
PIP Proximal interphalangeal joint
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • proximal urinary tubule
    ±ÙÀ§ ¼¼´¢°ü
    ½Å ¼Òü¿¡¼­ Çî·¹¾¾ °í¸®¿¡ À̸£´Â ¿ä ¼¼°üÀÌ°í ½Å ¼Òü µÑ·¹¿¡¼­ ¿ìÃøÀ¸·Î ±¸ºÎ·¯Áø ±ÙÀ§ ¿ì°îºÎ¿Í ¼ö¹æ¼±À̳ª ¼öÁú ¼Ó¿¡ »¸¾î¼­ Á÷ÇàÇÏ´Â ±ÙÀ§Á÷ºÎ·Î ÀÌ·ç¾îÁø´Ù. Å©±â´Â 40-60umÀÌ°í »óÇÇ Á¶Á÷Àº °­ÇÑ »êÈ£¼ºÀ» ³ªÅ¸³»¸ç ÀÚÀ¯ Ç¥¸éÀº ¼âÀÚ¿¬, ±âÀúºÎ¿¡´Â ±âÁ¶ ¼±Á¶°¡ ¶Ñ·ÇÇÏ°Ô ¹ß´ÞÇϰí ÀÖ´Ù. ¼¼Æ÷°£ °¨¾ÐÀÌ ¹ß´ÞÇϰí ÀÎÁ¢ÇÑ ¼¼Æ÷ÀÇ °æ°è°¡ ºÒÈ®½ÇÇÏ´Ù. ¿©±â¼­´Â ¿ø´¢ ÁßÀÇ ¼öºÐ°ú ÀüÇØ ÁßÀÇ 75%°¡ Ç÷¾× ¼Ó¿¡ ÀçÈí¼öµÇ°í ¾Æ¹Ì³ë»êÀ̳ª Æ÷µµ´çµµ ÀçÈí¼öµÈ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
agonal clot Intravascular thrombosis ascribed to the process of dying.
(05 Mar 2000)
antemortem clot A blood clot, found at autopsy, formed in any of the heart cavities or the great vessels before death.
(05 Mar 2000)
blood clot <haematology> The conversion of blood from a liquid form to solid through the process of coagulation.
A thrombus is a clot which forms inside of a blood vessel. If that clot moves inside the vessel it is referred to as an embolus (embolism). The presence of atherosclerotic plaque lining blood vessel walls is a significant stimulus for clot formation.
(27 Sep 1997)
passive clot A clot formed in an aneurysmal sac consequent to the cessation or slowing of circulation through the aneurysm.
(05 Mar 2000)
medication, clot-dissolving Drugs used to dissolve blood clots. Agents such as plasminogen-activator (t-pa) and streptokinase that are effective in dissolving clots and re-opening arteries. Used, for example, in the treatment of heart attacks. Clot-dissolvers are also called thrombolytic agents.
(12 Dec 1998)
chicken fat clot Clot formed in vitro or postmortem from leukocytes and plasma of sedimented blood.
(05 Mar 2000)
clot 1. To coagulate, said especially of blood.
2. A soft, nonrigid, insoluble mass formed when a liquid (e.g., blood or lymph) gels.
Origin: O.E. Klott, lump
(05 Mar 2000)
clot-dissolving medications Agents such as plasminogen-activator (t-PA) and streptokinase that are effective in dissolving clots and re-opening arteries. Used, for example, in the treatment of heart attacks. Also called thrombolytic agents.
(12 Dec 1998)
clot retraction Retraction of a clot resulting from contraction of platelet pseudopods attached to fibrin strands that is dependent on the contractile protein thrombosthenin. Used as a measure of platelet function.
(12 Dec 1998)
clot retraction time The time required for a blood clot to separate from the tube wall and express serum, usually completed in 18 to 24 hours, but retarded or absent in persons with thrombocytopenic purpura.
(05 Mar 2000)
mucin clot test A test that reflects the polymerization of synovial fluid hyaluronate; a few drops of synovial fluid added to acetic acid form a clot; poor clot formation occurs in a variety of inflammatory conditions including septic arthritis, gouty arthritis, and rheumatoid arthritis.
Synonym: Ropes test.
(05 Mar 2000)
postmortem clot A clot formed in the heart or great vessels after death.
(05 Mar 2000)
currant jelly clot A jelly-like mass of red blood cells and fibrin formed by the in vitro or postmortem clotting of whole or sedimented blood.
(05 Mar 2000)
Schede's clot Filling of the defect in bone, after removal of a sequestrum or scraping away carious material, by allowing the cavity to fill with blood which may become organised (Schede's clot).
(05 Mar 2000)
euglobulin clot lysis time A measure of the ability of plasminogen activators and plasmin to lyse a clot; normally, clot lysis is determined by the balance of factors which activate fibrinolysis (plasminogen activators and plasmin) and those which inhibit lysis; in certain conditions (e.g., carcinoma or hepatic insufficiency) activating factors predominate and can be measured by noting the time it takes the euglobulin fraction of plasma (excluding inhibitors of fibrinolysis) to clot.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á